By the time patients ask WBMA about neuromodulation therapy, they’re usually tired of hearing, “Give the medication more time.” Some have already done that for years. Therapy helped, medication helped a little, and daily life still feels heavier than it should.
This guide walks through how each option works, where the FDA status differs, and what a patient can reasonably expect. You can also explore our full neuromodulation therapy services for details on getting started.
How Neuromodulation Works for Mental Health Conditions
Mood and anxiety symptoms often involve more than one brain region acting alone. The prefrontal cortex, limbic system, attention networks, and stress-response systems can all be part of the picture. Neuromodulation works at the circuit level more directly than oral medication, through one of two broad mechanisms.
Magnetic or electrical methods
TMS, tDCS, and eTNS apply stimulation from outside the body. Neurofeedback is different because it trains the brain using real-time feedback rather than stimulation.
Medication-based methods
Ketamine and Spravato act rapidly on the glutamate system and may support changes in synaptic plasticity.
That circuit-level focus does not replace the rest of mental health care. At WBMA, neuromodulation is usually considered alongside psychiatry, therapy, medication management, and diagnostic testing when those pieces are clinically appropriate.
Neuromodulation Therapy Options at WBMA
WBMA offers six neuromodulation approaches for mental health. Each option has its own protocol, FDA status, safety profile, and evidence base.
TMS Therapy
A magnetic coil near the scalp sends focused pulses to mood-regulating regions. Patients stay awake, with no anesthesia. Most often used for major depressive disorder after antidepressants have not helped enough; some systems are also cleared for OCD.
TMS therapy at WBMAKetamine Therapy
Works on the glutamate system and is studied for treatment-resistant depression, with some patients noticing changes within hours to days. Psychiatric IV ketamine is off-label; ketamine is FDA-approved only as an anesthetic.
Ketamine therapySpravato / Esketamine
A nasal-spray esketamine, FDA-approved for treatment-resistant depression (2019) and for depressive symptoms in adults with MDD with acute suicidal ideation or behavior (2020). Given only in certified settings under the FDA's REMS program.
Spravato and ketamine benefitsNeurofeedback
Uses EEG to give real-time feedback so a patient can practice changing patterns linked with attention, stress, or anxiety. No medication and no external stimulation. Not FDA-cleared to treat a specific psychiatric diagnosis.
Neurofeedback at WBMAtDCS
A low-intensity electrical current through scalp electrodes that modulates targeted brain regions. Studied for mood and cognitive symptoms and generally well tolerated. Not FDA-cleared for a specific psychiatric diagnosis.
tDCS at WBMAeTNS
Mild electrical stimulation to branches of the trigeminal nerve via a small external device. The FDA cleared an eTNS device for pediatric ADHD; other psychiatric uses are off-label and used within a supervised plan.
eTNS at WBMANeuromodulation Therapy at a Glance
This table is meant to orient you before a consultation. Your diagnosis, medical history, and treatment goals still drive the final plan.
| Treatment | Best fit | FDA status | Typical course | Insurance notes |
|---|---|---|---|---|
| TMS Therapy | Treatment-resistant depression, OCD, anxious depression | FDA-cleared for MDD and OCD, by device and protocol | Daily sessions, often 4 to 6 weeks | Often covered for TRD; verify with insurer |
| Ketamine Therapy | Treatment-resistant depression, severe episodes | Off-label psychiatric use | Series of infusions; maintenance varies | Typically not covered |
| Spravato | TRD; MDD with acute suicidal ideation or behavior | FDA-approved (2019, 2020) | Twice weekly for 4 weeks, then adjusted | Possible with prior authorization |
| Neurofeedback | Anxiety, ADHD-related difficulties, stress | Not cleared for a specific diagnosis | Multiple sessions over weeks to months | Varies by plan |
| tDCS | Mood and cognitive symptoms (supportive) | Investigational for psychiatric use | Repeated short sessions over weeks | Generally not covered |
| eTNS | Mood and attention symptoms (supportive) | Cleared for pediatric ADHD; else off-label | Daily home use under guidance | Varies |
Who Is a Good Candidate for Neuromodulation Therapy?
No single patient profile fits every neuromodulation treatment. TMS screening is different from Spravato screening, and neurofeedback has a different risk conversation than ketamine. You may be a reasonable candidate for a neuromodulation evaluation if you:
- Live with a diagnosed condition such as depression, OCD, anxiety, PTSD, or ADHD-related symptoms.
- Completed adequate treatment trials with medication, therapy, or another first-line approach.
- Had limited relief or only partial response from those treatments.
- Experience medication side effects that make effective dosing difficult.
- Want an evidence-informed option that doesn't rely mainly on daily oral medication.
Candidacy also depends on medical history, current medications, and the specific treatment. TMS screening includes seizure history and metal implants near the head. A consultation with an interventional psychiatry clinician is the safest way to determine which option, if any, fits your situation.
Is Neuromodulation Safe and Does It Work?
These are the two questions patients ask most, and both deserve a direct answer.
On safety
TMS is non-invasive with a favorable safety record for appropriately selected patients. Ketamine and Spravato can cause short-term dissociation, sedation, and blood pressure changes, so they are given under monitoring. Neurofeedback, tDCS, and eTNS carry lower physical risk, though clinical fit still matters.
On effectiveness
For treatment-resistant depression, TMS and Spravato have the clearest FDA-recognized psychiatric uses. IV ketamine has research support but remains off-label. Evidence for neurofeedback, tDCS, and eTNS in psychiatric care continues to develop. Results vary by patient.
FDA Approval and Evidence Base
Regulatory status can be confusing because “available,” “studied,” “FDA-cleared,” and “FDA-approved” do not mean the same thing. Patients should ask exactly which device, medication, and protocol a clinic uses.
- TMS. The FDA has cleared TMS devices for major depressive disorder, and some systems or protocols are cleared for OCD.
- Spravato. FDA-approved for treatment-resistant depression and for depressive symptoms in adults with MDD with acute suicidal ideation or behavior. Administered only in certified settings under a REMS program.
- IV ketamine. Ketamine is FDA-approved as an anesthetic. Psychiatric IV ketamine is an off-label use, supported by clinical research but without a specific psychiatric FDA approval.
- Neurofeedback. Used clinically as a brain-training method. Not FDA-cleared to treat a specific psychiatric diagnosis.
- tDCS. Psychiatric use remains investigational in the United States, with no FDA clearance for a specific psychiatric diagnosis.
- eTNS. The FDA cleared an eTNS device for pediatric ADHD, while other psychiatric uses are off-label.
What to Expect From Treatment at WBMA
Neuromodulation at WBMA starts with a psychiatric evaluation. Your clinician reviews diagnosis, medication history, prior treatment response, medical risks, and current symptoms.
If one of these options appears appropriate, the team explains the protocol, visit schedule, monitoring plan, and progress measures. WBMA also offers psychiatry, therapy, and diagnostic testing, which can make coordination simpler for patients who need more than one service.
Cost and Insurance Coverage
Coverage varies by treatment, diagnosis, and insurance plan. TMS is often covered for treatment-resistant depression when prior-authorization criteria are met. Spravato may be covered with prior authorization because it has FDA-approved psychiatric indications.
IV ketamine is generally not covered for psychiatric care because that use is off-label. Coverage for neurofeedback, tDCS, and eTNS varies widely. Verify benefits with your insurer before starting treatment, and ask WBMA about the authorization process.
Frequently Asked Questions
Does insurance cover neuromodulation therapy?
Often, but it depends on the treatment and your plan. TMS and Spravato are more likely to be covered for treatment-resistant depression when prior-authorization criteria are met. IV ketamine, neurofeedback, tDCS, and eTNS vary more, so verify benefits before starting.
How is neuromodulation different from medication?
Daily oral medication affects neurotransmitter activity across the brain. Neuromodulation uses more targeted methods, including magnetic pulses, electrical stimulation, feedback training, or rapid-acting medication-based approaches, often alongside therapy and medication management.
Is neuromodulation safe long-term?
For appropriately selected patients, non-invasive options such as TMS have a favorable safety record. Long-term data varies by treatment, and durability of response differs, so a clinician reviews risks and maintenance planning first.
What is the difference between TMS and ECT?
TMS uses focused magnetic pulses while the patient is awake, with no anesthesia and mild, temporary side effects. ECT uses electrical stimulation under general anesthesia to induce a brief, controlled seizure, so it is a different treatment with a different intensity and risk profile.
Is neuromodulation effective for treatment-resistant depression?
TMS and Spravato have the clearest FDA-recognized psychiatric uses for TRD, and many properly selected patients improve, though results are not uniform. A psychiatric consultation is the right place to decide whether a specific option fits.
Ready to explore neuromodulation therapy?
Our psychiatry-led team evaluates each patient individually and is honest about what each treatment can and cannot offer.
Schedule a consultation Explore neuromodulation services
